163 related articles for article (PubMed ID: 26497980)
1. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
[TBL] [Abstract][Full Text] [Related]
2. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099
[TBL] [Abstract][Full Text] [Related]
4. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
5. Curcumin inhibits oral squamous cell carcinoma proliferation and invasion via EGFR signaling pathways.
Zhen L; Fan D; Yi X; Cao X; Chen D; Wang L
Int J Clin Exp Pathol; 2014; 7(10):6438-46. PubMed ID: 25400722
[TBL] [Abstract][Full Text] [Related]
6. Cobalt chloride stimulates phosphoinositide 3-kinase/Akt signaling through the epidermal growth factor receptor in oral squamous cell carcinoma.
Ryu MH; Park JH; Park JE; Chung J; Lee CH; Park HR
Biocell; 2010 Apr; 34(1):15-21. PubMed ID: 20506627
[TBL] [Abstract][Full Text] [Related]
7. Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.
Yasui H; Ohnishi Y; Nakajima M; Nozaki M
Oncol Rep; 2017 Jun; 37(6):3674-3680. PubMed ID: 28440510
[TBL] [Abstract][Full Text] [Related]
8. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
[TBL] [Abstract][Full Text] [Related]
11. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
12. Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling.
Chen HJ; Lin CM; Lee CY; Shih NC; Amagaya S; Lin YC; Yang JS
Int J Oncol; 2013 Aug; 43(2):629-37. PubMed ID: 23754208
[TBL] [Abstract][Full Text] [Related]
13. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
[TBL] [Abstract][Full Text] [Related]
15. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
[TBL] [Abstract][Full Text] [Related]
16. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
Rossow L; Eke I; Dickreuter E; Cordes N
Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
[TBL] [Abstract][Full Text] [Related]
17. Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.
Chang JW; Kang SU; Shin YS; Seo SJ; Kim YS; Yang SS; Lee JS; Moon E; Lee K; Kim CH
Sci Rep; 2015 Dec; 5():18208. PubMed ID: 26655729
[TBL] [Abstract][Full Text] [Related]
18. Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells.
Berndt A; Büttner R; Gühne S; Gleinig A; Richter P; Chen Y; Franz M; Liebmann C
Exp Cell Res; 2014 Apr; 322(2):402-14. PubMed ID: 24394543
[TBL] [Abstract][Full Text] [Related]
19. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
